Emisphere Technologies, Inc.
https://emisphere.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Emisphere Technologies, Inc.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Ipsen Dives Back Into Dealmaking With First ADC Pact
The French drugmaker has teamed up with South San Francisco's Sutro Biophgarma to bag the rights to a preclinical-stage ADC targeting ROR1.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
Quantum Outperforms Classical Computer, Finding New KRAS Inhibitors
In a breakthrough for drug discovery, quantum hardware outperformed classical hardware in generating two promising KRAS inhibitors.
Company Information
- Industry
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Clinical Technologies Associates, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice